Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
US senators accuse Novartis execs of greed for hiding manipulated Zolgensma data — and the next step could affect the industry
6 years ago
FDA+
AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study
6 years ago
R&D
Sarepta shares slammed on report gene therapy Duchenne MD patient was hospitalized, but the company says it is 'erroneous'
6 years ago
R&D
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
6 years ago
R&D
CMS will now cover pricey CAR-T therapies for Medicare patients
6 years ago
FDA+
Loxo chief Josh Bilenker steps in (temporarily) to head oncology R&D at Eli Lilly as Levi Garraway steps out
6 years ago
People
Teva to lose CFO, with turnaround still under construction
6 years ago
People
What’s a late-stage IL-23 drug worth these days? We’re about to find out
6 years ago
R&D
AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis, J&J in PARP race
6 years ago
R&D
Faced with another ethics scandal, Novartis CEO Vas Narasimhan assures analysts they tried to do 'the right thing'
6 years ago
FDA+
Gilead faces a hurdle in its race for big, add-on OK for Descovy as generic Truvada rivals loom
6 years ago
R&D
In draft guidance, NICE fails to back Clovis's PARP inhibitor Rubraca
6 years ago
FDA+
Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study
6 years ago
Roche scores a notable PhIII success with Tecentriq combo in bladder cancer, but is this another case of too little too late?
6 years ago
R&D
Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions
6 years ago
FDA chief backs 2 new pathways to spur drug importation — but analysts shrug it all off
6 years ago
People
Merck's Keytruda makes the cut as a second-line monotherapy for certain esophageal cancer patients
6 years ago
Bayer, Orion win speedy approval for prostate cancer drug darolutamide
6 years ago
FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
6 years ago
FDA+
What is Pfizer going to buy next? Albert Bourla outlines his M&A strategy in the post-Upjohn era
6 years ago
Deals
Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
6 years ago
In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval
6 years ago
Bristol-Myers does it again, disappointing investors with a surprise Opdivo PhIII failure as chemo combo flops
6 years ago
R&D
FDA OKs Humira copycat from Merck, Samsung Bioepis — but they will wait 4 years to launch
6 years ago
First page
Previous page
270
271
272
273
274
275
276
Next page
Last page